HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

HeartFlow reported FY2025 revenue of about $176 million, up 40% year over year, but posted a $116.8 million net loss and nearly negative $59.0 million in free cash flow. NovoCure generated roughly $655.4 million of FY2025 revenue, up 8.3%, but also remained unprofitable with a $136.2 million net loss and negative $75.7 million free cash flow. The article is largely comparative analysis, noting HeartFlow's lower leverage and stronger growth versus NovoCure's lower 2.5x P/S valuation and larger 2026 revenue outlook.

Analysis

The market is forcing a classic platform-vs-product choice, but the more important distinction is commercialization optionality. NVCR’s lower multiple is not just a value screen; it reflects a business that already has a meaningful installed treatment footprint and therefore more near-term operating leverage if reimbursement and adoption stay intact. HTFL’s richer multiple implies investors are paying for a longer-dated autonomous-AI story before the company has proven it can convert usage into durable free cash flow.

Second-order, HTFL’s risk is less about technology quality and more about the path from clinical utility to payment durability. If reimbursement tightens or the DOJ probe expands, utilization can slow faster than headline revenue suggests because diagnostic workflows are easier to defer than oncology treatment. NVCR’s vulnerability is different: its China expansion and geopolitically exposed manufacturing base create a binary overlay that can compress the valuation even if the core product continues to gain share.

The key contrarian point is that the low P/S on NVCR may still be the better setup because the upside doesn’t require a complete narrative reset, only evidence that the current patient base can be maintained while new indications and geographies ramp. By contrast, HTFL needs multiple things to go right simultaneously: broader adoption, no reimbursement compression, no legal overhang, and eventual margin inflection. That makes HTFL the higher-beta story, but not necessarily the better risk-adjusted one.

For a 6-12 month horizon, the cleaner expression is to own the business with the lower valuation and more visible operating base, while avoiding paying up for an unproven compounding curve. The biggest risk to that view is a sudden reimbursement or clinical setback for NVCR, which would re-rate the stock quickly; absent that, the current spread between the two names looks justified and may even widen if HTFL’s legal overhang becomes more costly.

Key Decisions for Investors

• Long NVCR vs. short HTFL as a relative-value pair for 6-12 months: NVCR has the more favorable valuation floor and better downside protection if growth disappoints, while HTFL still prices in a cleaner scaling path that looks fragile.
• If expressing outright exposure, favor a starter long in NVCR on 10-15% pullbacks rather than buying strength; risk/reward improves if the market continues to de-emphasize the China/geopolitics overlay and focus on revenue durability.
• Avoid initiating a fresh long in HTFL ahead of any litigation/reimbursement headlines; the stock is more vulnerable to multiple compression than fundamental upside over the next 1-3 quarters.
• For options players, consider NVCR call spreads 3-6 months out to capture a moderate rerating without paying for full directional upside; the thesis is valuation mean reversion, not explosive growth.
• If HTFL falls sharply on any regulatory or legal headline, it becomes a tactical bounce candidate only for short-term traders; the fundamental setup remains too dependent on multiple unproven catalysts.